Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 662pembrolizumab 612Magnetic Resonance Spectroscopy 565Carboplatin 451Cisplatin 400Cyclophosphamide 399Biopsy 385Nivolumab 329Paclitaxel 324Gemcitabine 317Radiotherapy 302Bevacizumab 250Dexamethasone 223fludarabine 217Docetaxel 203durvalumab 196Oxaliplatin 189venetoclax 188atezolizumab 188Fluorouracil 178Rituximab 177Pemetrexed 174Capecitabine 172Radiation 171Doxorubicin 168Radiosurgery 161Ipilimumab 149Etoposide 142Leucovorin 141Lenalidomide 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
C188-9 compound × 90 days × Clear all
NCT06141031 2026-05-27

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05440708 2026-04-27

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Tvardi Therapeutics, Incorporated

Phase 1/2 Recruiting
193 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡